# A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC

> **NCT04736823** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Akeso** · enrollment: 265 (actual)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** AK112
- **DRUG:** Pemetrexed
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT04736823
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-02-01
- **Primary completion:** 2026-07
- **Final completion:** 2026-12
- **Target enrollment:** 265 (ACTUAL)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04736823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04736823, "A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04736823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*